世邦魏理仕：2026年欧洲生命科学生态系统：地产投资指南（英文版）（97页）.pdf

1、REPORTEuropean Life Sciences Ecosystems:Sector Guide 2026Intelligent InvestmentEUROPELIFE SCIENCESCBRE RESEARCHFEBRUARY 20262CBRE RESEARCH 2026 CBRE,INC.Intelligent InvestmentEuropean Life Sciences Ecosystems:Sector Guide 2026|EuropeThe European life sciences sector remains at the forefront of innov

2、ation and growth,driven by technological breakthroughs,expanding scientific platforms,and a robust pipeline of new therapies.Advances across antibody-drug conjugates,AI-enabled drug discovery,precision medicine,metabolic and immunology-focused therapeutics,and digital health are increasingly complem

3、enting traditional medicines,a trend that underscores growing investor confidence and scientific ambition across the region.The sector encompasses a diverse set of sub-segments:biopharma/biotech,medical devices,diagnostics,contract research organisations,genomics,medtech,and digital health each play

4、ing a critical role in the overall life sciences ecosystem.On the funding front,venture capital(VC)investment into European life sciences rebounded strongly in 2025,with total healthcare and life sciences VC volumes reaching 13.22billion,up 2.8%on 2024,according to Pitchbook.At both European and nat

5、ional levels,life sciences continues to be recognised as a strategic priority for economies and governments,driven by its potential to improve public health outcomes,generate high-quality jobs,and contribute to GDP growth.At the same time,the ecosystem is strengthened by a large and growing pool of

6、university spin-outs.According to Cambridge Innovation Capital,European deep-tech and life sciences spin-outs are now collectively valued at c.$398billion,having created more than 167,000 jobs across over 7,300 companies.As start-ups scale and established companies consolidate their presence in high